The earnings report, which is expected to be released on July 29, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results ...

Since receiving the third-party audit findings for its Boston manufacturing facility in March, Integra has been thoroughly reevaluating its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site. Simultaneously, the Integra team has been furthering its plans to complete the construction and operationalization of the new state-of-the-art tissue manufacturing facility in Braintree. Based on these assessments, IART no longer intends to commence the manufacture of these products at ...

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is announcing its plans to restart the manufacture of PriMatrix® and SurgiMend® at its new manufacturing facility in Braintree, Massachusetts. The Company expects to operationalize this new facility in the first half of 2026. "Given the advantages of the Braintree facility and the challenges of the Boston facility, the decision to consolidate our efforts a ...

At Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in Mar ...

A month has gone by since the last earnings report for Integra LifeSciences (IART) . Shares have added about 26% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Integra's Q1 Earnings Match Estimates, Margins ...

Investors in Integra LifeScience Holdings Corporation (IART) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction o ...

Have you evaluated the performance of Integra LifeSciences' (IART) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gro ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 55 cents in the first quarter of 2024, down 25.7% year over year. The metric was in line with the Zacks Consensus Estimate.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall and EU Medical Device Regulation charges.GAAP loss per share in the first quarter was 4 cents against GAAP EPS of 29 cents in the year-ago quarter.Revenue DiscussionTota ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STAT ...

Integra LifeSciences Holdings Corporation [IART] Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Jan De Witte - President & CEO Lea Knight - CFO Chris Ward - IR Conference Call Participants Vik Chopra - Wells Fargo Steve Lichtman - Oppenheimer Kristen Stewart - C.L. King & Associates Robbie Marcus - J.P. Morgan Matt Taylor - Jefferies Ryan Zimmerman - BTIG Joanne Wuensch - Citigroup Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Jayson Bedford - Ra ...